Epigenetic therapy in MDS and acute AML: focus on decitabine

ISSN： 0939-5555

Source： Annals of Hematology, Vol.84, Iss.1, 2005-12, pp. : 1-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

By Wijermans P. Lübbert M. Verhoef G. Klimek V. Bosly A.

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 9-17

Springer Publishing Company

Access to resources Recommend Favorite

Decitabine: a historical review of the development of an epigenetic drug

By Vos Dick Overveld Wendy

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 3-8

Springer Publishing Company

Access to resources Recommend Favorite

Epigenetic regulation of tumor suppressors in t(8:21)-containing AML

By Yang Genyan

Annals of Hematology, Vol. 83, Iss. 6, 2004-06 ,pp. : 329-330

Springer Publishing Company

Access to resources Recommend Favorite

Epigenomics and epigenetic therapy of cancer

By Brown R. Strathdee G.

Trends in Molecular Medicine, Vol. 8, Iss. 4, 2002-04 ,pp. : 43-48

Elsevier

Access to resources Recommend Favorite

Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15 INK4b gene methylation and high global DNA methylation

By Lehmann Ulrich

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 275-277

Springer Publishing Company

Access to resources Recommend Favorite